FDA Approved: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for the fixed-dose inhaled combination budesonide and formoterol fumarate dihydrate from AstraZeneca (Symbicort).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

SUPPL AP for BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE)